NCT03458325 - Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 12, 2020

Primary Completion Date

June 24, 2021

Study Completion Date

June 24, 2021

Conditions

Heart Failure

Interventions

COMBINATION_PRODUCT

Furoscix Infusor

Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.

Trial Locations (8)

19001

Abington Hospital - Jefferson Health, Abington

27401

Moses H. Cone Memorial Hospital, Greensboro

33606

Tampa General Hospital, Tampa

46260

Ascension St. Vincent Heart Center, Indianapolis

50309

Unity Point Health, Des Moines

55422

University of Minnesota Medical Center, Minneapolis

91342

Olive View - UCLA Medical Center, Sylmar

06610

Bridgeport Hospital, Bridgeport

All Listed Sponsors

lead

scPharmaceuticals, Inc.

INDUSTRY